Dr. Bjorn Thorarinsson MD

Recommended Articles

• Alternative Treatments for Lung Cancer

  Lung cancer, also known as lung carcinoma is characterized by a malignant lung tumor caused by an uncontrolled growth of cells in tissues of the lungs. There are two main types of lung cancers-small cell lung cancer and non-small cell lung cancer. It is widely known that lung cancer is the most...

• New Technology Offers Shared Decision-Making for Cystic Fibrosis Patients

  Suffering from an autosomal recessive lethal disease is indubitably difficult, but what if there were something that could make it more manageable? Physician researchers at the University of Cincinnati have worked to develop a computerize decision-making model that assists cystic fibrosis patients...

• COPD: Know the Signs and Symptoms – Pink Puffers and Blue Bloaters

  COPD is a chronic lung condition that makes it difficult for you to breathe. Know about the signs and symptoms of chronic obstructive pulmonary disease (COPD), Blue Bloater and Pink puffer do not develop until the later stages of this disease. COPD is a term used to describe progressive lung...

• What is Tuberculosis?

  Tuberculosis, or TB, is a serious bacterial infection that often affects the lungs. It may also spread to other parts of the body, like the central nervous system, lymphatic system, and circulatory system. Treatment for tuberculosis may take a long time. The infectious organism may spread from one...

• What Are the Risk Factors for Lung Cancer?

  A risk factor could be any one of numerous influences that make you prone to developing cancer. There are unavoidable factors that you have no protection against. Some of these are a family history of genetically inherited traits, and age and gender issues. There are wholly avoidable factors such...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...